KalVista Pharmaceuticals, Inc. Common Stock

The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.

Related tickers: IONS, ATXS, NTLA, KALV, CAMP.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for CrowdStrike Holdings, Inc. (NASDAQ: CRWD) from $318 to $375. Keybanc analyst Eric Heath maintained an Overweight rating. CrowdStrike shares rose 0.4% to close at $322.44 on Tuesday. See how other analysts view this stock. Piper Sandler boosted Shopify Inc. (NYSE: SHOP) price target from $56 to $63. Piper Sandler analyst Clarke Jeffries maintained an Underweight rating. Shopify shares fell 13.4% to close at $77.18 on Tuesday. See how other analysts view this stock. Needham boosted the price target for SS&C Technologies Holdings, Inc. (NASDAQ: SSNC) from $62 to $70. Needham analyst Mayank Tandon maintained a Buy rating. SS&C Technologies shares fell 1.8% to close at $60.15 on Tuesday. See how other analysts view this stock. JP Morgan raised Bruker Corporation ...

Related tickers: BIIB, BRKR, DENN, C, HPQ, SSNC, SHOP, KALV, MDB, CRWD.